Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Image of a large glass building, the Sherard building located on the Oxford Science Park. The Oxford Science Park logo is on the top right. The Theolytics logo is on the bottom left.

Theolytics was one of the first companies to join the BioEscalator community in 2018.

Led by CEO/Co-Founder Charlotte Casebourne, named one of 30 Rising Leaders in Life Sciences in 2020 by In Vivo and featured in Forbes 30 under 30 Europe 2021: Science & Healthcare, Theolytics is a biotechnology company harnessing viruses to combat cancer. Its phenotypic screening platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population.

The company closed its Series A Round in January 2020 with $6.8M (£5M). The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI). It then received a boost with a grant from Innovate UK in November 2020. Recently, Theolytics' Series A funding has expanded as M Ventures joined the company's investor syndicate this month (July 2021). 

Theolytics was the winner of the BioEscalator's inaugural Pitch Finale, kindly supported by Santander Universities UK and received a cash prize along with a place in the final of BIO International Start-up Stadium on 8-12 June 2020. The judges selected the company as the most attractive to investors based on the company's pitch given by Charlotte Casebourne. 

Theolytics more than doubled its occupied space during its time at the BioEscalator. Growing steadily from a team of 4, the company now has 22 employees. The move to the Sherard Building at The Oxford Science Park will permit Theolytics' to expand and accelerate its work developing therapies for some of the most challenging cancers.


It's been fantastic to have been a part of the BioEscalator community since it opened in 2018. Being based in a purpose-built facility for early-stage life science businesses surrounded by others navigating through the early stages of building a biotech company has definitely made a difference. The core BioEscalator team are supportive and knowledgeable; we're looking forward to staying in touch as we graduate to The Oxford Science Park! 

Charlotte Casebourne - CEO, Theolytics


Click here to visit Theolytics' website